Adverse drug reactions observed during DOTS.

Simple item page
dc.contributor.authorDhingra, V Ken_US
dc.contributor.authorRajpal, Sen_US
dc.contributor.authorAggarwal, Nishien_US
dc.contributor.authorAggarwaln, J Ken_US
dc.contributor.authorShadab, Khanen_US
dc.contributor.authorJain, S Ken_US
dc.date.accessioned2004-12-02en_US
dc.date.accessioned2009-06-01T18:32:35Z
dc.date.available2004-12-02en_US
dc.date.available2009-06-01T18:32:35Z
dc.date.issued2004-12-02en_US
dc.description.abstractA total of 8.37% of the 1195 patients treated at NDTB Centre with DOTS under RNTCP between January 2002 to June 2003 presented with adverse drug reactions. Patients showing any sort of adverse reactions were studied in detail by personal interviews and a semi-structured questionnaire. The profile of patients presenting with adverse reactions showed that majority of the patients (53%) had gastrointestinal reactions, the commonest presenting complaint being nausea and vomiting. General aches and pains were complained by about 35% and giddiness was the presenting complaint in 27% irrespective of the use of streptomycin, although giddiness was observed more often in Category II patients (59%). Skin rash and itching was complained by about 17% of patients and 11% complained of arthralgia, while only 1% had hepatotoxicity during treatment. Majority of the adverse reactions (67%) were observed within the first four weeks of treatment and only 0.25% of patients treated with DOTS had interruption of treatment for short periods.en_US
dc.description.affiliationNew Delhi Tuberculosis Centre, Jawaharlal Nehru Marg, New Delhi-110 002.en_US
dc.identifier.citationDhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K, Jain SK. Adverse drug reactions observed during DOTS. Journal of Communicable Diseases. 2004 Dec; 36(4): 251-9en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/112300
dc.language.isoengen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntitubercular Agents --administration & dosageen_US
dc.subject.meshDirectly Observed Therapyen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshEthambutol --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshIndiaen_US
dc.subject.meshIsoniazid --administration & dosageen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNational Health Programsen_US
dc.subject.meshPatient Complianceen_US
dc.subject.meshPyrazinamide --administration & dosageen_US
dc.subject.meshRifampin --administration & dosageen_US
dc.subject.meshStreptomycin --administration & dosageen_US
dc.subject.meshTuberculosis --drug therapyen_US
dc.titleAdverse drug reactions observed during DOTS.en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Communicable Diseases